AbstractIntroduction: HPV16 is the most common viral subtype associated with malignant transformation, ranging between 90% and 95% of all cases [8]. It is present in 86.7% of all HPVpositive oropharyngeal SCCs compared with 68.2% of HPVpositive oral SCCs and 69.2% of HPVpositive laryngeal SCCs [9]. Prevalence of HPV in oral cancers is similar in Europe (16%) and North America (16.1%), but greater in Asia (33%) [9]. Data from multiple studies have indicated that HPVassociated tumors account for 20% to 75% of OPSCC. Methodology: Patient who fulfill the inclusion criteria and his/her care takers were explained regarding the nature of the disease, radical treatment with concurrent chemo radiation, its effectiveness and possible side effects. Patient were counseled about the ill effects of tobacco and alcohol consumption and asked to discontinue the same. Patients were also counseled regarding maintenance of good oral hygiene throughout the treatment, good nutritional support, adherence to the planned treatment. Results: In arm A, 60%(9/15) of patients had oral cavity cancer, 13.3%(2/15) of patients had oropharyeal cancer and 26.6% (4/15) patients had hypopharyngealcancer. In arm B, 65. 7% (23/35) of patients had oral cavity cancer, 8.5%(3/35) of patients had oropharyneal cancer, 5.7% (2/35) patietns had laryngeal cancer, 2.8%(1/ 35) patients had were in nasopharyeal cancer and 17.1%(6/35) were in hypopharyneal cancer. Conclusion: No association found in nodal (N) stage at presentation between HPV positive and negative tumors.
Keywords: HPV; Nasopharyeal Cancer; Head and Neck Cancer.